– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI chemotherapy   – – Randomized combination trial in second-line colorectal cancer patients to initiate

MOUNTAIN VIEW, Calif. , Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at the 41st Annual J.P.